Comparison of first-line treatment strategies for metastatic hormone-sensitive prostate cancer in Japanese clinical practice since 2020: a multicenter registry study

医学 恩扎鲁胺 中止 前列腺癌 肿瘤科 内科学 危险系数 临床终点 多西紫杉醇 临床试验 比例危险模型 毒性 阿比曲酮 前列腺特异性抗原 醋酸阿比特龙酯 雄激素剥夺疗法 临床实习 封锁 抗雄激素 放射治疗 随机对照试验 退伍军人事务部 联合疗法 临床研究阶段 不利影响 中期分析 代理终结点 生存分析 低风险 癌症 置信区间
作者
Takashi Ueda,Keita Hayakawa,Yuki Ota,Junki Murashita,Hikaru Takahashi,Yumiko Saito,Masatsugu Miyashita,Takumi Shiraishi,Atsuko Fujihara,Masayoshi Okumi,Yuta Asakawa,Yuki Harada,Takeshi Yamada,Osamu Ukimura
出处
期刊:Japanese Journal of Clinical Oncology [Oxford University Press]
标识
DOI:10.1093/jjco/hyag184
摘要

BACKGROUND: Though randomized trials established androgen-receptor signaling inhibitor (ARSI) doublets and darolutamide-docetaxel triplet therapy (TRI) for metastatic hormone-sensitive prostate cancer, combined androgen blockade (CAB) remains widely used in Japan and these strategies have not been compared directly. METHODS: We retrospectively analysed 643 men with M1 disease who began androgen-deprivation therapy during 2020-2026 at 23 Japanese institutions: CAB (113), abiraterone (139), enzalutamide (166), apalutamide (APA; 116), or TRI (109). The primary endpoint was castration-resistance-free survival (PFS1). Groups were compared by Kaplan-Meier analysis and multivariable Cox regression, with inverse-probability-of-treatment weighting, restriction to 2023-2026, and propensity-score matching as sensitivity analyses. RESULTS: Median PFS1 was 16.1, 37.5, 54.9, and 52.9 months, respectively, and was not reached with TRI (P < .001). Adjusted hazard ratios versus CAB were 0.50 (95% CI 0.34-0.72), 0.43 (0.28-0.66), 0.42 (0.26-0.66), and 0.20 (0.10-0.41); triplet versus pooled ARSI doublets was 0.45 (0.24-0.85), exploratory and resting on 12 events. The ordering was preserved in all sensitivity analyses. Prostate-specific antigen 90 (PSA90) rates were similar (94.7%-95.8%), whereas a PSA nadir ≤0.2 ng/ml rose from 43.4% (CAB) to 68.9% (triplet; P < .001). Overall survival was immature (141 deaths). Discontinuation for toxicity was most frequent with APA (19.8%); 54.1% of triplet-treated patients completed six docetaxel cycles. CONCLUSIONS: Intensified first-line treatment was associated with a substantially lower hazard of castration resistance than CAB. The further reduction with TRI rests on few events and is exploratory. Discontinuation for toxicity was most frequent with APA, but ascertainment differed between the registry streams, so safety comparisons are hypothesis-generating.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
夏日气泡水完成签到 ,获得积分10
刚刚
灵运完成签到,获得积分10
1秒前
虚幻缘郡完成签到,获得积分10
1秒前
2秒前
巫惜海发布了新的文献求助10
2秒前
2秒前
开心枣枣完成签到 ,获得积分10
2秒前
2秒前
3秒前
菁菁发布了新的文献求助10
3秒前
xigua123完成签到,获得积分10
3秒前
4秒前
cdercder的应助被楠楠采纳,获得10
4秒前
文静冰露发布了新的文献求助10
5秒前
李密发布了新的文献求助10
5秒前
6秒前
暴躁月亮发布了新的文献求助20
7秒前
fnana发布了新的文献求助10
7秒前
微风无起发布了新的文献求助10
8秒前
8秒前
zyt完成签到,获得积分20
8秒前
9秒前
余香的应助被1111采纳,获得10
9秒前
now发布了新的文献求助10
11秒前
qizhang发布了新的文献求助20
11秒前
11秒前
光头哥哥发布了新的文献求助10
11秒前
12秒前
12秒前
悲凉的雪珍完成签到 ,获得积分10
13秒前
安坤科研完成签到 ,获得积分10
14秒前
14秒前
袁xl完成签到,获得积分10
14秒前
15秒前
曾经凌萱发布了新的文献求助10
16秒前
王小西完成签到,获得积分10
16秒前
wgm完成签到,获得积分10
16秒前
阿申爱乐的应助被kingwill采纳,获得30
17秒前
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067